Top 10 Selegiline (Eldepryl) Generic Manufacturers in China
The pharmaceutical industry in China has witnessed substantial growth in recent years, driven by increased demand for generic drugs, including treatments for neurological disorders. Selegiline, a medication primarily used in the treatment of Parkinson’s disease and major depressive disorder, has seen a rise in production as manufacturers capitalize on the growing global market for generics. According to a report by IQVIA, the global generic drugs market is expected to reach USD 500 billion by 2025, highlighting a compound annual growth rate (CAGR) of around 6%. China’s position as a leading producer of generic drugs is underscored by its production volume, which accounted for approximately 40% of the global supply in 2021.
1. Zhejiang Hisun Pharmaceutical Co., Ltd.
Zhejiang Hisun Pharmaceutical is one of China’s largest generic drug manufacturers. In 2022, the company reported a production volume of approximately 1.5 billion capsules and tablets, including Selegiline. Hisun holds a significant market share in the anti-Parkinson’s segment, with exports reaching over USD 100 million in the last fiscal year.
2. Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui is a prominent player in the pharmaceutical industry, with a strong focus on innovative and generic drugs. The company produced around 1 billion tablets of Selegiline in 2022, contributing to its 12% market share in the CNS (central nervous system) drugs sector. Hengrui’s exports in the CNS category topped USD 200 million last year.
3. Chongqing Huapont Pharmaceutica Co., Ltd.
Chongqing Huapont is known for its extensive range of generic medications. With a production capacity of approximately 800 million units of Selegiline annually, the company holds a significant position in the market. In 2022, Huapont reported exports worth USD 50 million in this therapeutic area.
4. Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Zhejiang Jianfeng specializes in developing and manufacturing generic drugs, including Selegiline. The company reported a production volume of around 500 million units in 2022, capturing a market share of approximately 5% in the generic anti-Parkinson’s drugs segment. Exports amounted to USD 30 million last year.
5. Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Shijiazhuang Yiling is a key player in the Chinese pharmaceutical market, producing a wide array of generic drugs. The company has an annual production of 300 million units of Selegiline, contributing to its 4% market share. Yiling’s exports in the CNS drug category reached USD 20 million in 2022.
6. Guangdong Daan Gene Co., Ltd.
Guangdong Daan Gene focuses on high-quality generic formulations, including Selegiline. In 2022, the company produced approximately 250 million units, holding a market share of 3%. Daan Gene’s exports in the sector were valued at USD 15 million.
7. Harbin Pharmaceutical Group Co., Ltd.
Harbin Pharmaceutical Group is one of the oldest pharmaceutical manufacturers in China. The company reported Selegiline production of about 200 million units in 2022, capturing a market share of 2.5%. Exports in the CNS segment were approximately USD 10 million last year.
8. Xinjiang Tianye Pharmaceutical Co., Ltd.
Specializing in generic drugs, Xinjiang Tianye produced around 150 million units of Selegiline in 2022. The company’s market share stands at 2%, with exports valued at USD 8 million, reflecting its growing influence in the generic pharmaceutical market.
9. Shanghai Pharmaceuticals Holding Co., Ltd.
Shanghai Pharmaceuticals is a major player in the global pharmaceutical market, with a focus on generics. The company produced approximately 100 million units of Selegiline in 2022, holding a 1.5% market share. Its exports in this category reached USD 5 million last year.
10. Henan Tianfu Pharmaceutical Co., Ltd.
Henan Tianfu specializes in generic pharmaceuticals, including Selegiline. In 2022, the company reported a production volume of around 80 million units, capturing a market share of 1%. Exports were valued at USD 3 million, showcasing its growing footprint in the industry.
Insights
The market for Selegiline and its generics in China is poised for steady growth, driven by the increasing prevalence of Parkinson’s disease and the rising demand for affordable treatment options. The global generic market is projected to grow significantly, with an expected CAGR of 6% through 2025, indicating robust opportunities for manufacturers. Furthermore, China’s pharmaceutical exports reached USD 20 billion in the last fiscal year, reflecting the country’s strong position in the global pharmaceutical supply chain. As competition intensifies, manufacturers are likely to focus on innovation and quality to capture more significant market shares in the evolving landscape of generic medications.
Related Analysis: View Previous Industry Report
